How big is Marker Therapeutics, Inc.?

As of Jun 18, Marker Therapeutics, Inc. has a market capitalization of 16.97 million, classifying it as a Micro Cap company, with net sales of 5.70 million and a net profit of -12.79 million over the latest four quarters.

Market Cap: As of Jun 18, Marker Therapeutics, Inc. has a market capitalization of 16.97 million, classifying it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Marker Therapeutics, Inc. reported net sales of 5.70 million and a net profit of -12.79 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 18.56 million and total assets of 22.02 million.

What does Marker Therapeutics, Inc. do?

Marker Therapeutics, Inc. is an immuno-oncology company focused on developing peptide and gene-based immunotherapeutics and vaccines for cancer treatment. As of March 2025, it has a market cap of $16.97 million, with net sales of $0 million and a net loss of $4 million.

Overview: <BR>Marker Therapeutics, Inc. is an immuno-oncology company specializing in the development of peptide and gene-based immunotherapeutics and vaccines for cancer treatment, operating within the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 16.97 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.94 <BR>Return on Equity: -85.09% <BR>Price to Book: 1.17<BR><BR>Contact Details: <BR>Address: 3200 SOUTHWEST FREEWAY, SUITE 2250, HOUSTON TX: 77027 <BR>Tel: 1 713 4006400 <BR>Fax: 1 302 6555049 <BR>Website: https://markertherapeutics.com/

Should I buy, sell or hold Marker Therapeutics, Inc.?

Who are in the management team of Marker Therapeutics, Inc.?

As of March 2022, the management team of Marker Therapeutics, Inc. includes Mr. Frederick Wasserman (Independent Chairman), Mr. Peter Hoang (President and CEO), and Dr. Juan Vera (Chief Development Officer). The Board of Directors also features independent directors such as Mr. David Eansor and Mr. Steven Elms.

As of March 2022, the management team of Marker Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. Frederick Wasserman, Independent Chairman of the Board<BR>- Mr. Peter Hoang, President, Chief Executive Officer, and Director<BR>- Dr. Juan Vera, Chief Development Officer and Director<BR><BR>Additionally, the Board of Directors includes several independent directors: Mr. David Eansor, Mr. Steven Elms, Mr. David Laskow-Pooley, and Mr. John Wilson.

Is Marker Therapeutics, Inc. overvalued or undervalued?

Marker Therapeutics, Inc. is considered risky and overvalued due to significant losses, a negative ROE of -85.09%, and a year-to-date return of -69.13%, which underperforms the S&P 500's 12.22%.

As of 17 March 2022, the valuation grade for Marker Therapeutics, Inc. moved from does not qualify to risky. The company appears to be overvalued given its significant losses and negative returns across multiple periods. The Price to Book Value stands at 1.38, while the EV to Sales ratio is 1.11, indicating a premium relative to its sales despite the lack of profitability. Additionally, the ROE is a staggering -85.09%, reflecting severe inefficiencies in generating returns for shareholders.<BR><BR>In comparison to peers, Marker Therapeutics has a P/E ratio of -0.7992, while ImmunoPrecise Antibodies Ltd. shows a much higher P/E of -13.0409, and HOOKIPA Pharma, Inc. has a P/E of -0.1637, suggesting that Marker is struggling more than its counterparts. The company's stock has underperformed significantly against the S&P 500, with a year-to-date return of -69.13% compared to the index's 12.22%, reinforcing the notion that it is overvalued in the current market context.

Is Marker Therapeutics, Inc. technically bullish or bearish?

As of September 11, 2025, Marker Therapeutics, Inc. is in a bearish trend with weak strength, indicated by bearish MACD and moving averages, and a year-to-date return of -69.13% compared to the S&P 500's 12.22%.

As of 11 September 2025, the technical trend for Marker Therapeutics, Inc. has changed from mildly bearish to bearish. The current technical stance is bearish with weak strength. Key indicators driving this stance include a bearish MACD on the weekly timeframe, bearish moving averages on the daily timeframe, and a bearish KST on both weekly and monthly timeframes. The RSI shows bullish momentum on the weekly but lacks a clear signal on the monthly. Additionally, the stock has significantly underperformed against the S&P 500 across multiple periods, with a year-to-date return of -69.13% compared to the S&P 500's 12.22%.